non-small cell lung cancer
FDA Approves Thermo Fisher Scientific Oncomine Dx Assay as CDx for Janssen Lung Cancer Drug
The Oncomine Dx Target Test will be used as a companion diagnostic to identify NSCLC patients whose tumors carry EGFR Exon20-insertion mutations.
The company recently presented new results on the test's sensitivity and specificity, as well as its performance across specific nodule sizes and cancer stages.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Japanese Health Ministry Clears Thermo Fisher Scientific Oncomine Assay as CDx for Lung Cancer Drug
The Oncomine Dx Target Test can now be used to identify patients with RET-fusion positive NSCLC who may be treated with Eli Lilly's selpercatinib.
Amoy Diagnostics, Amgen Partner on Lung Cancer CDx Development for Lumakras in Japan
Amoy Diagnostics will develop its PCR-based panel as a companion diagnostic in Japan to screen NSCLC patients for Amgen's KRAS G12C inhibitor.
Dec 10, 2020
Lucence Obtains CLIA Certification for Palo Alto Lab
Nov 12, 2020